Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — 1H 2021 Earnings Presentation
12 slides from Novonesis A/s Class B's earnings presentation, Aug 12, 2021
Slide 1: Conference call 1H 2021
Conference call 1H 2021 August 12, 2021
Slide 2: Forward Looking Statement
Disclaimer Forward Looking Statement This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limite
Slide 3: Highlights
Highlights 1H 2021 Q2 2021 Strong Q2 with 9% organic sales growth. Full-year outlook for organic sales and EBIT Realized Realized margin narrowed to high ends of ranges; ROIC incl. goodwill raised Sales performance, organic % 6 9 • Novozymes reaches a strategic milestone in the implementation of its
Slide 4: Household Care 32% of sales
Household Care Performance in line with expectations 2021 perspectives • Organic 1H sales growth y/y: -2% (Q2 y/y: -6%). • Enzyme penetration in emerging markets. • Continued growth from increased enzymatic penetration in • Freshness rollout with broad-market launch. emerging markets and the Freshne
Slide 5: Food, Beverages & Human Health 24% of sales
Food, Beverages & Human Health Strong performance, full-year outlook raised 2021 perspectives • Organic sales growth 1H y/y: 14% (Q2 y/y: 18%). • Food performance driven by innovation, emerging markets • Strong performance above expectations; all subareas and penetration and health-focused solutions
Slide 6: Bioenergy 17% of sales
Bioenergy Strong growth on top of COVID-19 impacted 1H’20 2021 perspectives • Organic sales growth 1H y/y: 16% (Q2 y/y: 54%). • Growth driven by gradual recovery in U.S. ethanol • Strong performance driven by recovery in U.S. ethanol production, capacity expansion in Latin America, and production an
Slide 7: Grain & Tech Processing 15% of sales
Grain & Tech Processing Strong performance across most subareas 2021 perspectives • Organic sales growth 1H y/y: 17% (Q2 y/y: 18%). • Growth expected across most subareas. • Better than expected development mainly due to stock • Innovation and market penetration driving growth in building. grain, an
Slide 8: Agriculture, Animal Health & Nutrition 12% of sales
Agriculture, Animal Health & Nutrition Decline as expected against difficult comparator 2021 perspectives • Organic sales growth 1H y/y: -9% (Q2 y/y: -19%). • Double-digit underlying growth in agriculture from • Decline due to negative base effects from BioAg one-off and expansion across crops and r
Slide 9: Financials – Performance 1H
Financials – Performance 1H Strong performance across sales, earnings and cash flow, including currency headwinds and M&A- related effects • Organic sales growth 1H y/y: +6%; DKK sales +3% y/y. • Strong gross margin at 58.4%, 210bps higher than last year driven by production efficiencies and product
Slide 10: Outlook 2021
Outlook 2021 Organic sales growth and EBIT margin outlook narrowed to high ends of previous ranges. All business areas expected to grow in 2021 • Organic sales growth of 4% to 6% with sales in reported DKK slightly less than 1p.p. lower — all business areas expected to grow in 2021. • EBIT margin at
Slide 11: Summary: Better business with biology
Summary Strong Q2 with 9% organic sales growth. Full-year outlook for organic sales and EBIT margin narrowed to high ends of ranges; ROIC incl. goodwill raised • 2021 outlook updated: Organic sales guidance narrowed upwards to 4% to 6%, while still subject to COVID-19 uncertainty and expected 2H des
Slide 12: Slide 12